STOCK TITAN

Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR) announces that CEO Chandler Robinson will present at two upcoming conferences. The 34th Annual Roth Conference is scheduled for March 14, 2022, at 1:30 PM Pacific Time, at The Ritz Carlton in Laguna Niguel, California. The Maxim’s 2022 Virtual Growth Conference will take place on March 30, 2022, at 4:30 PM Eastern Time. Monopar focuses on therapeutics aimed at improving the lives of cancer patients, with a pipeline that includes Validive® and camsirubicin.

Positive
  • None.
Negative
  • None.

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference.

Presentation Details:

34th Annual Roth Conference

https://www.roth.com/conferences/upcoming-conferences
Date: March 14, 2022
Time: 1:30pm Pacific Time
Location: The Ritz Carlton, Laguna Niguel located in Dana Point, California

Maxim’s 2022 Virtual Growth Conference

https://www.m-vest.com/home
Date: March 30, 2022
Time: 4:30pm Eastern Time
Location: https://m-vest.com/events/2022-virtual-growth-conference

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced  severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:   

Monopar Therapeutics Inc. 
Investor Relations   
Kim R. Tsuchimoto   
Chief Financial Officer   
kimtsu@monopartx.com 

Follow Monopar on social media for updates:  
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics 


FAQ

What is Monopar Therapeutics doing at the 34th Annual Roth Conference?

Monopar Therapeutics will be represented by CEO Chandler Robinson, who will present at the conference on March 14, 2022.

When is the Maxim’s 2022 Virtual Growth Conference?

The Maxim’s 2022 Virtual Growth Conference will be held on March 30, 2022, at 4:30 PM Eastern Time.

What is the stock symbol for Monopar Therapeutics?

The stock symbol for Monopar Therapeutics is MNPR.

What is the focus of Monopar Therapeutics?

Monopar Therapeutics is focused on developing therapeutics designed to extend life and improve the quality of life for cancer patients.

Where will the 34th Annual Roth Conference take place?

The 34th Annual Roth Conference will take place at The Ritz Carlton in Laguna Niguel, California.

Monopar Therapeutics Inc.

NASDAQ:MNPR

MNPR Rankings

MNPR Latest News

MNPR Stock Data

125.56M
3.01M
42.94%
24.47%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMETTE